On June 4, 2025, the Cure Hepatitis C Act of 2025/2026 (S.1941/H.R.9682) was introduced with bipartisan cosponsorship in both chambers. While this is the most comprehensive hepatitis C virus (HCV) specific bill ever introduced in Congress, it requires significant changes…
From Concern to Action: Concrete Ways You Can Help Protect Progress on HIV, TB, and HCV
Treatment Action Group (TAG) welcomes the introduction of the House companion to the Cure Hepatitis C Act (S.1941) and applauds Representatives Diana DeGette (D-CO), Mariannette Miller-Meeks (R-IA), Hank Johnson (D-GA), and Don Bacon (R-NE) for advancing bipartisan legislation to eliminate hepatitis C in the United States. We are particularly encouraged that the House bill removes the immigration-based eligibility restrictions contained in Section 10 of the Senate version — an important improvement that brings the legislation closer to the public health principles necessary to achieve hepatitis C virus (HCV) elimination in the United States in our lifetimes.
Treatment Action Group (TAG) has submitted formal comments opposing a proposed rule from the White House Office of Management and Budget (OMB) that would overhaul how federal research grants are awarded and managed. Under the proposed rule changes, scientific experts would still review research applications, but political appointees would have final authority to approve, deny, or cancel awards based on alignment with the administration's priorities.
The White House Office Of Management and Budget (OMB) under the direction of Russell Vought is seeking a regulatory blessing to use Federal grant funding as a tool for political extortion, violation of due process, and further undermining of scientific integrity. Targets include scientists, institutions, organizations, States, cities, and other recipients who might fail an extreme right wing, Christian nationalist, anti-science political litmus test.
Treatment Action Group (TAG) is profoundly troubled by recent reporting that the NIH’s longstanding Notice of Funding Opportunity (NOFO) process is being interrupted and delayed by political interference.
CDC pauses rabies, mpox, and other infectious disease testing amid budget cuts and staffing losses, raising urgent public health concerns.
TAG recommends that the AIDS Research Advisory Council (ARAC) endorse NIAID's continued support of a balanced and comprehensive portfolio of basic, clinical, and implementation science — including a funding opportunity to renew its four current networks: the Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG), the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT), the HIV Prevention Trials Network (HPTN), and the HIV Vaccine Trials Network (HVTN) or the updated IBPTN.
We're seeking a highly organized and technically proficient Administrator to support the organization as it continues to grow. This position reports to TAG’s Director of Finance. This is a full-time, salaried role.
TAG condemns the United States’ war in Iran and neighboring countries. At a time when U.S. investment in public health is being slashed, the Trump administration has chosen to spend billions of dollars per day on weapons used in a war of choice for which no credible rationale has been proposed. Our government should invest in our communities by spending funds that were already appropriated and illegally impounded by the White House Office of Management and Budget to keep people healthy, rather than starting new wars that put the entire world’s health at risk.